

Claudio Micheletto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2940022/publications.pdf>

Version: 2024-02-01

78
papers

1,251
citations

393982

19
h-index

433756

31
g-index

81
all docs

81
docs citations

81
times ranked

1859
citing authors

#	ARTICLE	IF	CITATIONS
1	Omalizumab Modulates Bronchial Reticular Basement Membrane Thickness and Eosinophil Infiltration in Severe Persistent Allergic Asthma Patients. <i>International Journal of Immunopathology and Pharmacology</i> , 2012, 25, 475-484.	1.0	106
2	Comorbidities, Cardiovascular Therapies, and COVID-19 Mortality: A Nationwide, Italian Observational Study (ItaliCO). <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 585866.	1.1	63
3	Salmeterol & Fluticasone 50 $\hat{1}$ / ₄ g/250 $\hat{1}$ / ₄ g bid in combination provides a better long-term control than salmeterol 50 $\hat{1}$ / ₄ g bid alone and placebo in COPD patients already treated with theophylline. <i>Pulmonary Pharmacology and Therapeutics</i> , 2003, 16, 241-246.	1.1	58
4	Tobramycin Nebulizer Solution in severe COPD patients colonized with <i>Pseudomonas aeruginosa</i> : effects on bronchial Inflammation. <i>Advances in Therapy</i> , 2008, 25, 1019-1030.	1.3	56
5	Galectin-3: an early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months. <i>Clinical and Translational Allergy</i> , 2017, 7, 6.	1.4	55
6	Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. <i>International Journal of COPD</i> , 2016, 11, 597.	0.9	44
7	Changes in blood ROS, e-NO, and some pro-inflammatory mediators in bronchial secretions following erdosteine or placebo: A controlled study in current smokers with mild COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2008, 21, 304-308.	1.1	42
8	Asthmatic patients in COVID-19 outbreak: Few cases despite many cases. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 541-542.	1.5	40
9	Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience. <i>BMC Pulmonary Medicine</i> , 2016, 16, 128.	0.8	38
10	Montelukast 10 mg improves nasal function and nasal response to aspirin in ASA-sensitive asthmatics: a controlled study vs placebo. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2004, 59, 289-294.	2.7	37
11	Severe asthma in adults does not significantly affect the outcome of COVID-19 disease: Results from the Italian Severe Asthma Registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 902-905.	2.7	37
12	COVID-19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 871-874.	2.7	33
13	Prevalence of tracheobronchomalacia and excessive dynamic airway collapse in bronchial asthma of different severity. <i>Multidisciplinary Respiratory Medicine</i> , 2013, 8, 32.	0.6	31
14	Small airway dysfunction and bronchial asthma control : the state of the art. <i>Asthma Research and Practice</i> , 2015, 1, 13.	1.2	29
15	Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. <i>European Annals of Allergy and Clinical Immunology</i> , 2011, 43, 45-53.	0.4	28
16	A Two-Stage Logistic Model Based on the Measurement of Pro-Inflammatory Cytokines in Bronchial Secretions for Assessing Bacterial, Viral, and Non-Infectious Origin of COPD Exacerbations. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2005, 2, 7-16.	0.7	25
17	Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1205-1212.	1.0	25
18	Costs of asthma in Italy: Results of the SIRIO (Social Impact of Respiratory Integrated Outcomes) study. <i>Respiratory Medicine</i> , 2007, 101, 2511-2519.	1.3	23

#	ARTICLE	IF	CITATIONS
19	Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1386-1388.	2.0	21
20	Changes in urinary LTE4 and nasal functions following nasal provocation test with ASA in ASA-tolerant and -intolerant asthmatics. <i>Respiratory Medicine</i> , 2006, 100, 2144-2150.	1.3	19
21	Omaliuzumab management beyond clinical trials: The added value of a network model. <i>Pulmonary Pharmacology and Therapeutics</i> , 2014, 29, 74-79.	1.1	19
22	CT radiomic models to distinguish COVID-19 pneumonia from other interstitial pneumonias. <i>Radiologia Medica</i> , 2021, 126, 1037-1043.	4.7	18
23	Nasal and bronchial tolerability of Rofecoxib in patients with aspirin induced asthma. <i>European Annals of Allergy and Clinical Immunology</i> , 2006, 38, 10-4.	0.4	18
24	Aspirin induced asthma (AIA) with nasal polyps has the highest basal LTE4 excretion: a study vs AIA without polyps, mild topic asthma, and normal controls. <i>European Annals of Allergy and Clinical Immunology</i> , 2006, 38, 20-3.	0.4	18
25	Erdosteine affects eicosanoid production in COPD. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2011, 49, 41-45.	0.3	17
26	ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. <i>World Allergy Organization Journal</i> , 2021, 14, 100592.	1.6	17
27	Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 59, 101855.	1.1	16
28	Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019, 16, 215-226.	0.7	16
29	Exercise prehabilitation in lung cancer: Getting stronger to recover faster. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1847-1855.	0.5	16
30	Relevance of TH2 Markers in the Assessment and Therapeutic Management of Severe Allergic Asthma: A Real-Life Perspective. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 35-41.	0.6	15
31	Changes in Total IgE Plasma Concentration Measured at the Third Month during Anti-IgE Treatment Predict Future Exacerbation Rates in Difficult-to-Treat Atopic Asthma: A Pilot Study. <i>Journal of Asthma</i> , 2011, 48, 437-441.	0.9	14
32	The Burden of Short-Acting β_2 -Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program. <i>Advances in Therapy</i> , 2021, 38, 3816-3830.	1.3	14
33	Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1579-1590.	1.8	14
34	Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD. <i>Therapeutic Advances in Respiratory Disease</i> , 2008, 2, 271-277.	1.0	13
35	Assessment of inhaled BDP-dose dependency of exhaled nitric oxide and local and serum eosinophilic markers in steroids-naive nonatopic asthmatics. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2003, 58, 1018-1022.	2.7	12
36	Vitamin D and disease severity in coronavirus disease 19 (COVID-19). <i>Reumatismo</i> , 2021, 72, 189-196.	0.4	12

#	ARTICLE	IF	CITATIONS
37	Prevalence of gastro-oesophageal reflux in asthmatics: an Italian study. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1999, 31, 371-5.	0.5	11
38	Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma. <i>Respiratory Medicine</i> , 2005, 99, 850-855.	1.3	10
39	Health and social impacts of COPD and the problem of under-diagnosis. <i>Multidisciplinary Respiratory Medicine</i> , 2014, 9, 63.	0.6	10
40	Subglottic Malt-Lymphoma of the Larynx: An Unusual Presentation of Chronic Cough. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 461-465.	1.0	10
41	The prevalence of nasal polyps and the corresponding urinary LTE4 levels in severe compared to mild and moderate asthma. <i>European Annals of Allergy and Clinical Immunology</i> , 2010, 42, 120-4.	0.4	9
42	Lung metastasis from TTF-1 positive sigmoid adenocarcinoma. pitfalls and management. <i>Pathologica</i> , 2013, 105, 69-72.	1.3	9
43	Pharmacokinetics of the Effect of Nebivolol 5mg on Airway Patency in Patients with Mild to Moderate Bronchial Asthma and Arterial Hypertension. <i>Clinical Drug Investigation</i> , 2002, 22, 197-204.	1.1	8
44	Outcomes and costs of treating chronic obstructive pulmonary disease with inhaled fixed combinations: the Italian perspective of the PATHOS study. <i>International Journal of COPD</i> , 2014, 9, 569.	0.9	8
45	Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 817-829.	0.8	8
46	How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center. <i>Frontiers in Oncology</i> , 2021, 11, 669786.	1.3	8
47	Near fatal asthma: treatment and prevention. <i>European Annals of Allergy and Clinical Immunology</i> , 2016, 48, 116-22.	0.4	8
48	Cost analysis of GER-induced asthma: A controlled study vs. atopic asthma of comparable severity. <i>Respiratory Medicine</i> , 2007, 101, 1814-1820.	1.3	7
49	A MCh Test Pre-post Esophageal Acidification in Detecting GER-related Asthma. <i>Journal of Asthma</i> , 2009, 46, 351-355.	0.9	7
50	Pattern of airway inflammation and remodelling in mild persistent atopic asthma and in mild persistent asthma related to gastroesophageal reflux. <i>European Annals of Allergy and Clinical Immunology</i> , 2012, 44, 236-42.	0.4	6
51	Changes of clinical outcomes and health care resources in moderate and in severe COPD treated uniquely with tiotropium 18µg od for twenty-four months. <i>Pulmonary Pharmacology and Therapeutics</i> , 2011, 24, 373-376.	1.1	5
52	Reference urinary LTE4 levels in normal individuals: a pilot study. <i>European Annals of Allergy and Clinical Immunology</i> , 2011, 43, 22-8.	0.4	5
53	Evidence of Adequacy of the Performance of the Pulvinalâ„¢ by Measuring Through-Device Peak Inspiratory Flow Rate in Severe Airways Obstruction in Adults and Children. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2001, 14, 343-349.	1.2	4
54	Additive Effects of Montelukast on Bronchial Hyperresponsiveness to MCh and LTE4 Urine Levels in Mild-persistent Atopic Asthmatics Assuming ICS. <i>Chest</i> , 2004, 126, 814S.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Effects of tiotropium and formoterol on quiet breathing pattern assessed by optoelectronic plethysmography in COPD patients: a pilot study. <i>Therapeutic Advances in Respiratory Disease</i> , 2012, 6, 97-105.	1.0	4
56	Prevalence of asymptomatic SARS-CoV-2-positive individuals in the general population of northern Italy and evaluation of a diagnostic serological ELISA test: a cross-sectional study protocol. <i>BMJ Open</i> , 2020, 10, e040036.	0.8	4
57	Effect of inhaled beclomethasone dipropionate and budesonide dry powder on pulmonary function and serum eosinophil cationic protein in adult asthmatics. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 1999, 9, 241-7.	0.6	4
58	Future Perspectives of Revaluating Mild COPD. <i>Respiration</i> , 2022, 101, 688-696.	1.2	4
59	<p>A Framework For Step Down Or Therapeutic Re-Organization For Withdrawal Of Inhaled Corticosteroids In Selected Patients With COPD: A Proposal For COPD Management</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2185-2193.	0.9	3
60	Severe asthma management in the era of biologics: insights of the Italian Registry on Severe Asthma (IRSA). <i>European Annals of Allergy and Clinical Immunology</i> , 2021, 53, 103.	0.4	3
61	Severe Asthma in adolescents and adults: a National, multicenter registry in real life. <i>European Annals of Allergy and Clinical Immunology</i> , 2018, 50, 196.	0.4	3
62	Urinary LTE4 is higher after nasal provocation test with L-ASA in bronchial than in only nasal responders. <i>European Annals of Allergy and Clinical Immunology</i> , 2007, 39, 162-6.	0.4	3
63	The impact of LABA+ICS fixed combinations on morbidity and economic burden of COPD in Italy: a six-year observational study. <i>Therapeutic Advances in Respiratory Disease</i> , 2011, 5, 83-90.	1.0	2
64	Overcoming Barriers to the Effective Management of Severe Asthma in Italy. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 481-491.	1.5	2
65	Serum eosinophil cationic protein and bronchial hyperresponsiveness to hyposmolar challenge in naive atopic asthmatics. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 1998, 8, 294-9.	0.6	2
66	CT-based radiomics as a tool to recognize COVID-19 positive patients. <i>Physica Medica</i> , 2021, 92, S46.	0.4	2
67	Hypo-osmolar aerosol induces hyperventilation in chronic non-asthmatic rhinitics. <i>Respiratory Medicine</i> , 1998, 92, 9-13.	1.3	1
68	EOSINOPHILIC INFLAMMATION AND BASEMENT MEMBRANE THICKNESS (BMT) IN ATOPIC AND IN GER-RELATED ASTHMA. <i>Chest</i> , 2005, 128, 147S.	0.4	0
69	BASEMENT MEMBRANE THICKNESS, EOSINOPHILIC INFLAMMATION AND URINARY LTE4 IN PATIENTS WITH NASAL POLYPS WITH OR WITHOUT BRONCHIAL ASTHMA. <i>Chest</i> , 2007, 132, 507A.	0.4	0
70	PRS28 ADD-ON OMALIZUMAB IN PERSISTENT DIFFICULT-TO-TREAT ASTHMA: A 12-MONTH STUDY ON CLINICAL, ECONOMIC OUTCOMES AND RELATED COST/UTILITY. <i>Value in Health</i> , 2009, 12, A303-A304.	0.1	0
71	Erdosteine But Not Placebo Reduces The Exercise-induced Oxidative Stress In Severe COPD. , 2010, , ,		0
72	Sensitivity And Specificity Of A Nucleic Acid Amplification Test (AMT-BK) For Tuberculosis Detection. , 2010, , ,		0

#	ARTICLE	IF	CITATIONS
73	Potential Economic Impact Of Inhalation Errors Due To Device Switch In Patients With Chronic Obstructive Pulmonary Disease And Asthma. Value in Health, 2015, 18, A370.	0.1	0
74	Complicazioni nei pazienti in ossigenoterapia domiciliare a lungo termine. , 2006, , 113-122.		0
75	Clinical Outcomes. , 2012, , 195-210.		0
76	Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis. , 2018, , .		0
77	Role of different spirometric reference equations for lung volumes assessment. , 2018, , .		0
78	The therapeutic effects of inhaled long-acting beta2-adrenergics (LABA) and corticosteroids (ICS) are not affected by their inhalation sequence in moderate/persistent asthma. European Annals of Allergy and Clinical Immunology, 2006, 38, 153-7.	0.4	0